Abstract:
OBJECTIVE To develop a liquid chromatography-tandem mass spectrometry(LC-MS/MS) method for detecting venetoclax plasma concentrations in pediatric patients and to apply it in clinical practice.
METHODS Venetoclax plasma concentrations were determined by LC-MS/MS with venetoclax-d8 adopted as the internal standard after protein precipitation. An Eclipse Plus C18 (100 mm×2.1 mm, 3.5 μm) column was used for separation with a mobile phase consisting of 0.1% formic acid and 2 mmol·L−1 ammonium acetate in water(A) and 0.1% formic acid in acetonitrile(B) at 65% B for isocratic elution. The flow rate was 0.4 mL·min−1, column temperature was 40 °C, injection volume was 1 μL, and total analysis time was 2 min. The electrospray ionization source coupled with positive ion and multiple reaction monitoring mode was applied. The quantitative and qualitative ion pairs were m/z 868.30→321.15, m/z 868.30→177.10 for venetoclax and m/z 876.25→329.25, m/z 876.25→177.25 for venetoclax-d8, respectively. The method was validated for specificity, linearity, repeatability, matrix effect, precision, accuracy, stability, dilution effect, carry-over, and recovery. Plasma samples from 7 pediatric patients with acute myeloid leukemia(AML) treated with venetoclax were determined.
RESULTS An LC-MS/MS method was successfully developed for quantifying venetoclax concentrations in pediatric plasma samples. The linear range was 0.05−5.00 mg·L−1(r=0.999 6), and the lower limit of quantification was 0.05 mg·L−1. Across all quality control concentrations, intra- and inter-batch precision were between 1.77% and 6.25%, while the assay accuracy ranged from 96.17% to 106.24%. Normal plasma matrix, 15% hyperlipidemic plasma matrix, and 5% hemolysis plasma matrix did not interfere with the determination of venetoclax plasma concentrations. Plasma samples were stable when kept in the autosampler for 24 h, at room temperature for 24 h, and after three freeze-thaw cycles. No carryover effect was observed in the quantitative analysis of venetoclax. A total of 14 plasma samples involving 7 pediatric patients with AML were determined. The trough concentration(C0) of venetoclax ranged from 0.126 to 1.620 mg·L−1, and the peak concentration(C6) ranged from 0.791 to 2.639 mg·L−1.
CONCLUSION The established LC-MS/MS assay exhibited satisfactory analytical performance that complies with the requirements of the reference method. The pretreatment procedure is simple, requiring only 20 μL of plasma, which is suitable for pediatric venetoclax pharmacokinetic investigations and routine therapeutic drug monitoring.